Search
phenylbutazone (Butazolidin)
Tradename: Butazolidin.
Pharmacokinetics:
1) metabolized to pharmacologically active metabolites
a) oxyphenbutazone (t1/2 of 72 hours)
b) 2-hydroxyphenbutasone (uricosuric)
2) after a single dose, glucuronidation is dominant reaction
3) passive reabsorption in distal renal tubule
Adverse effects:
1) peptic ulcer
2) hypersensitivity reactions
3) ulcerative stomatitis
4) hepatitis
5) nephritis
6) aplastic anemia
7) agranulocytosis
8) leukopenia
9) thrombocytopenia
Drug interactions:
1) enhances anticoagulant effect of warfarin
2) may enhance hypoglycemic effect of sulfonylureas
3) may decrease concentrations of digoxin, digitoxin
Laboratory:
1) specimen: serum, plasma (EDTA); unstable in solution
2) methods: color, GLC, HPLC
3) spectophotomery measures drug & metabolite
4) GLC measures drug only
5) HPLC measures drug, but has poor response to metabolite
6) labs with Loincs
- phenylbutazone in specimen
- phenylbutazone in gastric fluid
- phenylbutazone in serum/plasma
- phenylbutazone in urine
Interactions
drug interactions
drug adverse effects of NSAIDs
monitor with non steroidal anti-inflammatory agents (NSIADs)
General
non-steroidal anti-inflammatory agent (NSAID)
Properties
INHIBITS: cyclooxygenase
MISC-INFO: elimination route LIVER
1/2life 50-72 HOURS
therapeutic-range 50-100 UG/ML
toxic-range >100 UG/ML
protein-binding 92-99%
Database Correlations
PUBCHEM correlations
References
- Clinical Guide to Laboratory Tests, 3rd edition, NW Tietz
ed, WB Saunders, Philadelphia, 1995
- Harrison's Principles of Internal Medicine, 14th ed.
Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1906
- Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed.,
W.B. Saunders, 1995